{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:30:38Z","timestamp":1762543838625,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro Airc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009448","name":"University of Campania Luigi Vanvitelli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["ID263"],"award-info":[{"award-number":["ID263"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017A95NCJ"],"award-info":[{"award-number":["2017A95NCJ"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Campania Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007065","name":"Universit\u00e0 degli Studi di Salerno","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20160"],"award-info":[{"award-number":["20160"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bmc.2023.117444","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T16:47:52Z","timestamp":1691858872000},"page":"117444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["2-Substituted 1,5-benzothiazepine-based HDAC inhibitors exert anticancer activities on human solid and acute myeloid leukemia cell lines"],"prefix":"10.1016","volume":"93","author":[{"given":"Simona","family":"De Vita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Meninno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Colarusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giovanna","family":"Chini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Lauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romolo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"De Cicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Sian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Nebbioso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1788-5170","authenticated-orcid":false,"given":"Giuseppe","family":"Bifulco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117444_b0005","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejmech.2018.08.073","article-title":"HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors","volume":"158","author":"Sangwan","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112831","article-title":"Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment","volume":"208","author":"Peng","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101312","article-title":"Epigenetic enzymes: a role in aging and prospects for pharmacological targeting","volume":"67","author":"Pasyukova","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.bmc.2023.117444_b0020","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8797206","article-title":"HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases","volume":"2016","author":"Hull","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.bmc.2023.117444_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103184","article-title":"Small molecule HDAC inhibitors: promising agents for breast cancer treatment","volume":"91","author":"Huang","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0030","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors, insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.578011","article-title":"Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials","volume":"11","author":"Hontecillas-Prieto","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.bmc.2023.117444_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2023.117444_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112844","article-title":"Paradigm shift of \u201cclassical\u201d HDAC inhibitors to \u201chybrid\u201d HDAC inhibitors in therapeutic interventions","volume":"209","author":"Vaidya","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0050","doi-asserted-by":"crossref","first-page":"114156","DOI":"10.18632\/oncotarget.23169","article-title":"HDAC inhibition potentiates immunotherapy in triple negative breast cancer","volume":"8","author":"Terranova-Barberio","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmc.2023.117444_b0055","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/med.21505","article-title":"Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer","volume":"38","author":"Hesham","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2023.117444_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8120568","article-title":"Molecular docking simulations on histone deacetylases (HDAC)-1 and -2 to investigate the flavone binding","volume":"8","author":"Scafuri","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.bmc.2023.117444_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/nu12041010","article-title":"Flavonoids as epigenetic modulators for prostate cancer prevention","volume":"12","author":"Izzo","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.bmc.2023.117444_b0070","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41429-021-00459-6","article-title":"Naturally occurring small molecule compounds that target histone deacetylases and their potential applications in cancer therapy","volume":"74","author":"Maemoto","year":"2021","journal-title":"J Antibiot"},{"key":"10.1016\/j.bmc.2023.117444_b0075","first-page":"971","article-title":"Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in Vivo1","volume":"7","author":"Vigushin","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2023.117444_b0080","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/10428194.2018.1492122","article-title":"Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study","volume":"60","author":"Walewski","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bmc.2023.117444_b0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol Med"},{"key":"10.1016\/j.bmc.2023.117444_b0090","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1080\/10428194.2017.1298751","article-title":"A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas","volume":"58","author":"Sborov","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bmc.2023.117444_b0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2023.117444_b0100","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2023.117444_b0105","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2023.117444_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25194394","article-title":"Bifunctional HDAC therapeutics: one drug to rule them all?","volume":"25","author":"Smalley","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2023.117444_b0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","article-title":"Inhibitors of histone deacetylase as antitumor agents: a critical review","volume":"67","author":"Manal","year":"2016","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0120","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0125","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2023.117444_b0130","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.bmc.2013.04.036","article-title":"Structural basis for the design and synthesis of selective HDAC inhibitors","volume":"21","author":"Di Micco","year":"2013","journal-title":"Biorg Med Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1021\/ml1001163","article-title":"Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors","volume":"1","author":"Binaschi","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117444_b0140","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.ejmech.2008.05.035","article-title":"1,5-Benzothiazepine, a versatile pharmacophore: a review","volume":"43","author":"Bariwal","year":"2008","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0145","doi-asserted-by":"crossref","first-page":"70619","DOI":"10.1039\/C5RA12422K","article-title":"Benzothiazepines: chemistry of a privileged scaffold","volume":"5","author":"Saha","year":"2015","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmc.2023.117444_b0150","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1039\/c3cc41422a","article-title":"Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A","volume":"49","author":"De Vreese","year":"2013","journal-title":"Chem Commun"},{"key":"10.1016\/j.bmc.2023.117444_b0155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/chem.201604167","article-title":"Synthesis of potent and selective HDAC6 inhibitors bearing a cyclohexane- or cycloheptane-annulated 1,5-benzothiazepine scaffold","volume":"23","author":"De Vreese","year":"2017","journal-title":"Chem Eur J"},{"key":"10.1016\/j.bmc.2023.117444_b0160","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/chem.201700837","article-title":"Catalytic enantioselective synthesis of protecting-group-free 1,5-benzothiazepines","volume":"23","author":"Meninno","year":"2017","journal-title":"Chem Eur J"},{"key":"10.1016\/j.bmc.2023.117444_b0165","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.1039\/C8OB01988F","article-title":"Catalytic enantioselective one-pot approach to cis- and trans-2,3-diaryl substituted 1,5-benzothiazepines","volume":"16","author":"Meninno","year":"2018","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0170","unstructured":"LigPrep. Schr\u00f6dinger LLC, Schr\u00f6dinger Release 2021-1. New York, NY; 2021."},{"key":"10.1016\/j.bmc.2023.117444_b0175","unstructured":"QikProp. Schr\u00f6dinger LLC, Schr\u00f6dinger Release 2021-1. New York, NY; 2021."},{"key":"10.1016\/j.bmc.2023.117444_b0180","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1039\/D2CC01550A","article-title":"Identification of mercaptoacetamide-based HDAC6 inhibitors via a lean inhibitor strategy: screening, synthesis, and biological evaluation","volume":"58","author":"Geurs","year":"2022","journal-title":"Chem Commun"},{"key":"10.1016\/j.bmc.2023.117444_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101235","article-title":"Pharmacological properties of Trichostatin A, focusing on the anticancer potential A, comprehensive review","volume":"15","author":"Bouyahya","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmc.2023.117444_b0190","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bmc.2023.117444_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184700","article-title":"Vorinostat (SAHA) and breast cancer: an overview","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2023.117444_b0200","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nchembio.1223","article-title":"Selective class TMstone deacetylase inhibition via a nonchelating zinc-binding group","volume":"9","author":"Lobera","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2023.117444_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18050954","article-title":"Tubacin, an HDAC6 selective inhibitor, reduces the replication of the Japanese encephalitis virus via the decrease of viral RNA synthesis","volume":"18","author":"Lu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2023.117444_b0210","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11262","article-title":"Insights into the activation mechanism of class I HDAC complexes by inositol phosphates","volume":"7","author":"Watson","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2023.117444_b0215","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.bmcl.2010.03.091","article-title":"Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl)benzamides","volume":"20","author":"Bressi","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2023.117444_b0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature10728","article-title":"Structure of HDAC3 bound to co-repressor and inositol tetraphosphate","volume":"481","author":"Watson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2023.117444_b0225","doi-asserted-by":"crossref","first-page":"26694","DOI":"10.1074\/jbc.M803514200","article-title":"Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain","volume":"283","author":"Bottomley","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0230","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2023.117444_b0235","doi-asserted-by":"crossref","first-page":"11355","DOI":"10.1074\/jbc.M707362200","article-title":"Human HDAC7 harbors a vlass IIa histone deacetylase-specific zinc bnding motif and cryptic deacetylase activity","volume":"283","author":"Schuetz","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2023.117444_b0240","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","article-title":"Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases","volume":"12","author":"Somoza","year":"2004","journal-title":"Structure"},{"key":"10.1016\/j.bmc.2023.117444_b0245","unstructured":"Protein Preparation Wizard. Schr\u00f6dinger LLC, Schr\u00f6dinger Release 2021-1. New York, NY; 2021."},{"key":"10.1016\/j.bmc.2023.117444_b0250","unstructured":"CombiGlide. Schr\u00f6dinger LLC, Schr\u00f6dinger Release 2021-1. New York, NY; 2021."},{"key":"10.1016\/j.bmc.2023.117444_b0255","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623002924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623002924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:22:50Z","timestamp":1760836970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623002924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":51,"alternative-id":["S0968089623002924"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117444","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2-Substituted 1,5-benzothiazepine-based HDAC inhibitors exert anticancer activities on human solid and acute myeloid leukemia cell lines","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117444"}}